Abstract:LB-115 Mitochondrial malfunction, which can lead to decreased ATP generation through oxidative phosphorylation and altered drug sensitivity, has long been observed in many cancer cells, but the underlying mechanisms remain to be investigated. Here we report the establishment of an inducible cell model in which the mitochondrial respiratory function can be controlled by tetracycline and the use of this system as a tool to investigate on the relationship between mitochondrial respiratory malfunction, redox alterations, and drug sensitivity. A dominant negative form of the DNA polymerase gamma (POLGdn) was expressed in the T-ReX293 tetracycline inducible system. Mitochondrial malfunction was induced by doxocycline, which led to a almost complete suppression of oxygen consumption, caused by a depletion of the mitochondrial DNA-encoded respiratory chain complex I, III, IV, and V components, despite an increase of nuclear encoded complex II subunit proteins. Accompany with this mitochondrial respiratory defect, superoxide generation from the respiratory chain decreased, whereas cellular hydrogen peroxide level increased, as shown by fluorometric detection using hydroethedine and DCF-DA, respectively. The increase in hydrogen peroxide level was further confirmed by using the catalase to eliminate its specific fluorescent signal. Surprisingly, cellular nitric oxide level also increased when mitochondrial respiration was suppressed. The increase in nitric oxide could be inhibited by the NOS inhibitor L-NMMA. Biochemical analyses showed total cellular glutathione content and the expression of glutathione peroxidase (GPX-1) protein were elevated in the mitochondrial defective cells, whereas the levels of SOD1 and SOD2 proteins remained unchanged. These alterations in cellular redox states were associated with significant changes (increase or decrease) in cellular sensitivity to anticancer agents, depending on the mechanisms of action of the specific drugs. Compounds with pro-oxidant property are more effective in killing the cells with increased hydrogen peroxide and nitric oxide. These observations may have clinical implications in selecting proper drug to kill cancer cells with mitochondrial dysfunction.

Mitigation of NADH: ubiquinone oxidoreductase deficiency by chronic Trolox treatment

Biallelic Mutations in the Ferredoxin Reductase Gene Cause Novel Mitochondriopathy with Optic Atrophy

Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease

Complex I Deficiency in M.3243a>g Fibroblasts is Alleviated by Reducing NADH Accumulation

Abstract 224: Mitochondrial Complex I Deficiency Promotes Oxidative Stress During Ischemia Reperfusion of Cardiac Myocytes

Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects

Mitochondrial energetics is impaired in very long-chain acyl-CoA dehydrogenase deficiency and can be rescued by treatment with mitochondria-targeted electron scavengers

Loss of respiratory complex I subunit NDUFB10 affects complex I assembly and supercomplex formation

Partial loss of complex I due to NDUFS4 deficiency augments myocardial reperfusion damage by increasing mitochondrial superoxide/hydrogen peroxide production

Pathogenesis of mtDNA point mutation m.10191T>C affecting complex I function is a multifactorial process leading to metabolic remodeling of mitochondria

Mitochondrial cytochrome c oxidase deficiency.

Ndufs4 knockout mouse models of Leigh syndrome: pathophysiology and intervention

Mitochondrial Complex I Deficiency Increases Protein Acetylation and Accelerates Heart Failure.

Cell-permeable succinate prodrugs bypass mitochondrial complex I deficiency

Optimizing metabolism is a complex issue

Mitochondrial Respiratory Defects Lead to Significant Alterations in Cellular Redox States and Drug Sensitivity

RTN4IP1 is essential for the final stages of mitochondrial complex I assembly and coenzyme Q biosynthesis

ETHE1 and MOCS1 deficiencies: Disruption of mitochondrial bioenergetics, dynamics, redox homeostasis and endoplasmic reticulum-mitochondria crosstalk in patient fibroblasts

Combinatorial glucose, nicotinic acid and N-acetylcysteine therapy has synergistic effect in preclinical C. elegans and zebrafish models of mitochondrial complex I disease

Mitochondrial bioenergetics and cardiolipin remodeling abnormalities in mitochondrial trifunctional protein deficiency

Hypoxia and intra-complex genetic suppressors rescue complex I mutants by a shared mechanism